FDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026)
FDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026) Live odds across 5 markets: Full Approval at 83¢. Resolves Jul 1, 2026. Not financial
Resolves Jul 1, 2026
- Conditional / Accelerated Approval: Yes 6¢ (kalshi)
- Full Approval: Yes 83¢ (kalshi)
- Withdrawn by Sponsor: Yes 5¢ (kalshi)
- Denied (CRL Issued): Yes 5¢ (kalshi)
- No Decision: Yes 15¢ (kalshi)
LIVE
8sFDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026)
Resolves Jul 1, 2026
Total Volume
$551
+$73 (24h)
Active Markets
5
Across 1 platforms
Frontrunner
83¢
Full Approval
Biggest Mover 24h
-3¢
No Decision
Arb Opportunities
0
None detected
All Markets
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | 83¢ | 83¢ | $24+$18 24h | — | — | |
| 2 | 12¢ | 15¢ | $167+$9 24h | -3¢ | — | |
| 3 | 5¢ | 5¢ | $10+$9 24h | — | — | |
| 4 | 3¢ | 6¢ | $332+$19 24h | — | — | |
| 5 | 3¢ | 5¢ | $18+$18 24h | -2¢ | — |
Implied Probability
Consensus across platformsPrice History
Event Info
Whale Activity
Loading...